Buyback of Class B shares in Essity during week 51, 2025

Between December 15–19, 2025 Essity repurchased 73,113 Class B shares on Nasdaq Stockholm at a weighted average price of SEK 265.3285, for a weekly outlay of SEK 19,398,960 under the SEK 3bn buyback program announced April 23, 2025. Since the program start Essity has bought 9,165,538 shares (avg. SEK 258.4247) for SEK 2,368,601,473; treasury holdings stood at 9,948,038 Class B shares as of December 19, 2025, out of 693,054,489 total shares. Purchases were executed by BofA Securities Europe SA and financed from cash flow after the ordinary dividend, with management indicating continued buybacks as a recurring element of capital allocation.

Analysis

Market structure: The buyback (SEK 3bn program; ~9.17m shares bought at avg SEK 258.4, treasury ~9.95m = 1.44% of shares) directly benefits existing ESSITY-B holders via EPS accretion and marginal float tightening, creating technical support over days–months. Competitors (KMB, ULVR) are neutral operationally but may lose relative multiple if Essity’s recurring buyback policy is priced in. Cross-asset: negligible credit/commodity impact; slight positive SEK support and modest downward pressure on implied equity volatility as supply is soaked up.

Risk assessment: Tail risks include regulatory changes to EU buyback rules, an adverse consumer-health slowdown reducing cash flow (income sensitivity in Sweden/EM markets), or management prioritizing buybacks over capex causing medium-term organic growth declines. Immediate (days) effect = technical price support; short-term (weeks–months) = continued program through 2026 AGM can sustain outperformance; long-term (quarters) depends on margin trends and reinvestment discipline. Hidden dependencies: FX translation of SEK revenues and pension/funding needs could force program pause.

Trade implications: Tactical directional trade favors a modest long in ESSITY-B (Nasdaq Stockholm) funded by cash or shorts in global peers lacking buybacks (e.g., KMB). Options: use defined-risk call spreads to capture a 5–12% upside over 3–6 months and protective puts for downside >8%. Sector: overweight European hygiene/consumer staples vs cyclical consumer discretionary into Q1 2026 earnings.

Contrarian angles: Market may underprice the signal that buybacks will be recurring; however, if organic sales slip >100bps or management pivots to M&A, the buyback becomes a liquidity trap. Historically, buyback-driven EPS lifts (examples: Henkel, Unilever cycles) often outperformed for 3–9 months but reversed when underlying growth faded — watch margins, not just buyback size.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in ESSITY-B (Nasdaq Stockholm) sized in 2 tranches over the next 2–6 weeks; target take-profit at +10% or on completion of the SEK 3bn program, and cut to half size if price drops -6% or if adjusted EBIT margin falls >150bps vs last quarter.
• Implement a relative-value pair: long ESSITY-B 2% vs short KMB (Kimberly‑Clark, NYSE: KMB) 1.5% for 3–9 months to capture buyback-driven outperformance; unwind if Essity misses Q4 organic sales by >100bps or KMB reports better-than-expected margin expansion.
• Buy a 3-month call spread on ESSITY-B (long ATM ~270 SEK call, short 305 SEK call) sized to 0.5% of portfolio to express upside with defined risk; simultaneously purchase a 6-month 240 SEK put as downside insurance if premium <0.75% of the notional position.
• If Essity reports Q4 organic sales growth <1% or adjusted EBIT margin compresses >100bps (release expected within 60–100 days), reduce exposure to Essity and reallocate 1–2% into defensive staples ETFs (e.g., XLU-equivalents in Europe) within 5 trading days.